AdAlta Limited is an Australia-based clinical-stage biotechnology company. The principal business of the Company is the discovery and development of protein-based therapeutic and diagnostic products using its i-body platform. The Company has four active development programs ranging from discovery to Phase I clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product candidate, AD-214, is being developed as a anti-fibrotic therapeutic focusing initially on the degenerative and fatal orphan disease, Idiopathic Pulmonary Fibrosis (IPF) and related Interstitial Lung Diseases (ILDs), and with potential in other fibrotic diseases, particularly of the eye and kidney, and certain cancers. Its internal pipeline is focused on G-Protein Coupled Receptors (GPCRs) implicated in fibrotic and inflammatory diseases and cancer, and its external pipeline is leveraging partner expertise to pursue a range of targets and indications.